NCT06566508

Brief Summary

The objective of this study is to investigate \"clinically\" the effectiveness of Asiaticoside based intracanal medication compared to the commonly used intracanal medicaments (calcium hydroxide Ca(OH)2 and Ledermix) on the levels of bacteria and inflammatory cytokines in root canals and periradicular tissues of teeth with apical periodontitis.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
36

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Nov 2023

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 20, 2023

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 5, 2024

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

August 20, 2024

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 22, 2024

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 3, 2025

Completed
Last Updated

August 22, 2024

Status Verified

August 1, 2024

Enrollment Period

7 months

First QC Date

August 20, 2024

Last Update Submit

August 20, 2024

Conditions

Keywords

InflammationAsiaticosidePulpal necrosis

Outcome Measures

Primary Outcomes (1)

  • counting the number of colonies forming units of bacterial cells Microbiology cell culturing (manual counting technique to the bacterial cells) [Time Frame: up to 7 months]

    counting the number of colonies forming units of bacterial cells Microbiology cell culturing (manual counting technique to the bacterial cells) \[Time Frame: up to 7 months\]

    up to 7 months

Secondary Outcomes (1)

  • using enzyme-linked immunosorbent assay (ELISA test) to measure the amount of Inflammatory Cytokines (TNF-α), (IL-1β) and (PG2) ELISA test to measure the amount of tumor necrotizing factor (TNF-α), interleukin 1β(IL-1β) and prostaglandin E2 (PG2)

    up to 25 weeks

Study Arms (3)

Calcium Hydroxide

ACTIVE COMPARATOR

Intracanal medication

Drug: Calcium Hydroxide Intracanal medication

Leddermix

ACTIVE COMPARATOR

Intracanal medication

Drug: Leddermix Intracanal medication

Asiaticoside

ACTIVE COMPARATOR

Intracanal medication

Drug: Asiaticoside Intracanal medication

Interventions

Calcium Hydroxide Intracanal medication

Calcium Hydroxide

Leddermix Intracanal medication

Leddermix

Asiaticoside Intracanal medication

Also known as: centella asiatica
Asiaticoside

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Single-rooted with pulp necrosis and apical periodontitis.

You may not qualify if:

  • Receiving antibiotic treatment within the preceding 3 months.
  • Reporting systemic disease.
  • Teeth that could not be isolated with rubber dam.
  • Teeth with periodontal pockets deeper than 3 mm.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mansoura university

Al Mansurah, Egypt

RECRUITING

MeSH Terms

Conditions

InflammationDental Pulp Necrosis

Interventions

Centella asiatica extract

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsDental Pulp DiseasesTooth DiseasesStomatognathic DiseasesNecrosis

Study Officials

  • Amany Bader, prof

    Faculty of Dentistry Mansoura University

    STUDY DIRECTOR
  • Youssry Elhawary, prof

    Faculty of Dentistry Mansoura University

    STUDY DIRECTOR

Central Study Contacts

salem alqahtani, master

CONTACT

Ghada Abdelrazik

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

August 20, 2024

First Posted

August 22, 2024

Study Start

November 20, 2023

Primary Completion

June 5, 2024

Study Completion

March 3, 2025

Last Updated

August 22, 2024

Record last verified: 2024-08

Locations